



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/729,520	12/04/2000	Ana Rodriguez	GC647

CONFIRMATION NO. 4557

## FORMALITIES LETTER



\*OC00000007694486\*

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94034

Date Mailed: 03/21/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

2/3

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, Virginia, 22202 on the date shown below.

Date: May 14, 2002

By: Carol A. See

Carol A. See

**PATENT**  
**Docket No. GC647**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Rodriguez et al.

Serial No. 09/729,520

Filed: December 4, 2000

For: Method for Generating a Library of  
Mutant Oligonucleotides Using the  
Linear Cyclic Amplification Reaction )

# 8  
Group Art Unit: 1635

Examiner: Not Assigned

**STATEMENT OF SAMENESS**

Box Sequence, P.O. Box 2327  
Commissioner for Patents  
Arlington, VA 22202

Sir:

In accordance with 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d), the computer readable copy of the sequence listing, and the paper copy submitted herewith in the above application are believed to be the same. The present submission contains no new matter relative to the application as originally filed.

Respectfully submitted,

Date: 5/13/02

Kamrin T. MacKnight  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-5838  
Fax: 650-845-6504